As of 2024-12-15, the Relative Valuation of Arcus Biosciences Inc (RCUS) is (79.37) USD. This relative valuation is based on P/E multiples. With the latest stock price at 16.08 USD, the upside of Arcus Biosciences Inc based on Relative Valuation is -593.6%.
The range of the Relative Valuation is (81.32) - (83.68) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 27.6x - 40.2x | 34.4x |
| Forward P/E multiples | 19.0x - 28.4x | 19.4x |
| Fair Price | (81.32) - (83.68) | (79.37) |
| Upside | -605.7% - -620.4% | -593.6% |
| Date | P/E |
| 2024-12-13 | -5.45 |
| 2024-12-12 | -5.82 |
| 2024-12-11 | -6.09 |
| 2024-12-10 | -5.90 |
| 2024-12-09 | -5.92 |
| 2024-12-06 | -5.86 |
| 2024-12-05 | -5.80 |
| 2024-12-04 | -5.80 |
| 2024-12-03 | -5.57 |
| 2024-12-02 | -5.40 |
| 2024-11-29 | -5.23 |
| 2024-11-27 | -5.36 |
| 2024-11-26 | -5.35 |
| 2024-11-25 | -4.93 |
| 2024-11-22 | -4.98 |
| 2024-11-21 | -4.84 |
| 2024-11-20 | -4.96 |
| 2024-11-19 | -4.92 |
| 2024-11-18 | -4.89 |
| 2024-11-15 | -5.32 |
| 2024-11-14 | -5.34 |
| 2024-11-13 | -5.57 |
| 2024-11-12 | -5.68 |
| 2024-11-11 | -6.02 |
| 2024-11-08 | -6.05 |
| 2024-11-07 | -5.58 |
| 2024-11-06 | -5.33 |
| 2024-11-05 | -5.18 |
| 2024-11-04 | -5.27 |
| 2024-11-01 | -5.25 |
| 2024-10-31 | -5.19 |
| 2024-10-30 | -5.42 |
| 2024-10-29 | -5.56 |
| 2024-10-28 | -5.65 |
| 2024-10-25 | -5.53 |
| 2024-10-24 | -6.04 |
| 2024-10-23 | -5.87 |
| 2024-10-22 | -5.69 |
| 2024-10-21 | -5.75 |
| 2024-10-18 | -6.25 |
| 2024-10-17 | -6.18 |
| 2024-10-16 | -6.05 |
| 2024-10-15 | -6.03 |
| 2024-10-14 | -6.13 |
| 2024-10-11 | -6.23 |
| 2024-10-10 | -5.80 |
| 2024-10-09 | -6.01 |
| 2024-10-08 | -5.92 |
| 2024-10-07 | -5.86 |
| 2024-10-04 | -5.64 |